In-Office Procedures · Treatment (Rx)
Xdemvy (Lotilaner Ophthalmic Solution 0.25%): Demodex Blepharitis
The first and only FDA-approved prescription treatment for Demodex blepharitis, a frequently underdiagnosed driver of lid margin inflammation, MGD, and treatment-resistant dry eye.
Key points
- Prescription only, from Tarsus Pharmaceuticals.
- The first and only FDA-approved treatment for Demodex blepharitis.
- One drop in each eye twice daily for six weeks.
- Collarettes at the lash base are the key sign to look for.
Why Demodex matters in a dry eye practice
Demodex blepharitis (DB) is caused by overpopulation of Demodex mites (primarily Demodex folliculorum) in the eyelash follicles and meibomian glands. Collarettes, cylindrical, waxy dandruff-like deposits at the base of the eyelashes, are the pathognomonic sign of DB and can be visualized in seconds at the slit lamp with the patient looking down. DB is estimated to affect up to 58% of patients presenting with ocular surface symptoms, yet it is historically undertreated because no FDA-approved therapy existed before 2023.
Demodex overpopulation blocks meibomian gland orifices, triggers lid margin inflammation, and creates conditions that worsen evaporative dry eye. Patients with Demodex blepharitis often fail to respond adequately to standard MGD treatments until the mite load is controlled first.
How Xdemvy works
Xdemvy (lotilaner ophthalmic solution 0.25%) is instilled as one drop in each eye twice daily for six weeks. Lotilaner is a selective GABA-gated chloride channel inhibitor, it paralyzes and kills Demodex mites without affecting mammalian cells. The drug achieves therapeutic concentrations at the eyelid margin where the mites reside.
FDA approval & clinical evidence
- FDA approval, Xdemvy was approved by the FDA in July 2023 as the first and only treatment indicated specifically for Demodex blepharitis. Tarsus Pharmaceuticals FDA approval announcement
- SATURN-1 RCT (2023), 81% of Xdemvy-treated patients achieved clinically meaningful collarette reduction (grade 0 or 1) compared with 23% placebo at Day 43. 44% achieved complete collarette cure (grade 0). PMC, Drugs (first approval review)
- SATURN-2 RCT (2023), 89% of Xdemvy patients achieved clinically meaningful collarette reduction compared with 33% placebo. 56% achieved complete collarette cure. Xdemvy.com clinical data
- Mite eradication and erythema endpoints, Both trials demonstrated statistically significant reduction in mite density to zero confirmed by epilated lash microscopy, and significant cure of lid margin erythema at Day 43. PMC, Healthcare (2024 review)
- TFOS DEWS III (2025), Anti-Demodex therapies recognized as part of the lid hygiene treatment component for MGD, with Xdemvy cited as an approved pharmacological option. American Journal of Ophthalmology
Diagnosing Demodex blepharitis
Look for collarettes, cylindrical debris at the base of the eyelashes, during routine slit lamp examination with the patient looking down. Lid redness, itching, and recurrent chalazia are supporting signs. Collarettes are pathognomonic and visible without special equipment or staining. Educate patients that Demodex is a natural skin mite that can overpopulate; this is a medical condition, not a hygiene failure.
Manufacturer
Tarsus Pharmaceuticals, Xdemvy.com
Sources are linked inline above. Device descriptions reference FDA clearance status, published peer-reviewed studies, and manufacturer data. Clinical outcomes are not a guarantee of individual results. Review full prescribing information, the IFU, and FDA clearance documentation for each device before use.
